RBC Capital Markets Raises Price Target on Biogen to $272
RBC Capital Markets increased its price target for Biogen shares from $256 to $272 while maintaining an Outperform rating.
Stocks · News reference
Biogen to Present New Alzheimer's Disease Portfolio Data at 19th CTAD Conference
Biogen announced it will showcase new data from its Alzheimer's disease pipeline, including the Phase 2 CELIA study of diranersen and lecanemab, at the upcoming 19th Clinical Trials on Alzheimer's Disease (CTAD) Conference.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Wedbush Adjusts Price Target on Biogen to $225
Wedbush adjusted its price target for Biogen to $225 from $212, while maintaining a Neutral rating on the stock.
Barclays Raises Biogen Price Target to $230
Barclays increased its price target for Biogen shares from $200.00 to $230.00.